MayShu Medical Files IPO Prospectus: Delivering a Full-Lifecycle Women's Health Solution with Over 5,000 Units Installed Across More Than 10 Countries

Pelvic Organ Prolapse (POP) is a prevalent yet often unspoken pelvic floor dysfunction among women. It not only causes a series of symptoms, including vaginal wall bulging, uterine prolapse, defecation difficulties, and urinary abnormalities, but also negatively impacts patients’ social, professional, and emotional lives.

Currently, pelvic organ prolapse (POP) has become an increasingly serious public health issue. The Chinese Guidelines for the Diagnosis and Treatment of Pelvic Organ Prolapse categorize the management of POP into watchful waiting, non-surgical treatment, and surgical treatment. Among these, non-surgical treatment is recommended as the first-line therapy for all patients with POP.

Pelvic floor magnetic stimulation therapy, as a non-invasive, painless, and non-surgical treatment modality, has become an important means of improving diseases related to pelvic floor dysfunction. However, despite its many advantages, some pelvic floor magnetic stimulation devices currently on the market suffer from issues such as improper use, inconsistent equipment quality, and lack of compliant certification.

Amid the healthcare industry’s growing emphasis on regulatory compliance, medical device registration certificates serve not only as official endorsements of product safety and efficacy but also as a critical safeguard for patient safety and therapeutic outcomes.In March 2025, Guangzhou Meixiu Medical Technology Co., Ltd. (hereinafter referred to as “Meixiu Medical”) successfully obtained the Class II medical device registration certificate (Registration No.: Yue Xie Zhu Zhun 20252090383) and launched its pelvic floor magnetic stimulation therapy device, “MiCi Pro,” which was developed through five years of intensive research.

Meixiu Medical Pelvic Floor Magnetic Stimulation Therapy Device “MiCi Pro”

According to information from the official website of the National Medical Products Administration, MiCi Pro is the first pelvic floor magnetic stimulation device in China with clearly indicated indications for the “adjunctive treatment of pelvic organ prolapse, chronic pelvic pain, and vaginal laxity.”This achievement not only marks a significant step forward in the compliant development of Meixiu Medical, but also provides healthcare institutions and patients with legal and safe treatment options.

Image source: National Medical Products Administration

Meixiu Medical is a high-tech enterprise focused on women’s health, dedicated to providing comprehensive health management solutions for women through innovative technology. Its founder, Gong Zhaoyong, is an engineer with many years of experience in the upstream medical industry. Observing the limitations of traditional pelvic floor rehabilitation equipment in terms of convenience, efficacy, and safety in both his professional and personal life, Gong realized, “As an engineer with technical expertise, I have a responsibility to step forward and develop better devices to help women burdened by physiological and psychological stress overcome the challenges associated with pelvic floor rehabilitation.”

In a healthy state, the pelvic floor tissues act like a “hammock,” supporting the pelvic organs and maintaining them in their normal anatomical positions, thereby enabling functions such as urinary and fecal continence and maintaining vaginal tone. When this “hammock” is compromised, the position of the pelvic organs shifts, leading to a series of complications. To address health issues such as pelvic organ prolapse, chronic pelvic pain, and vaginal laxity, the MiCi Pro Pelvic Floor Magnetic Stimulation Therapist, developed by Meixiu Medical, offers four significant advantages: non-invasive, deeper penetration, broader coverage, and enhanced safety.

First is "non-invasive."Pelvic Floor Magnetic Stimulation TherapyPelvic floor magnetic stimulation therapy is based on Faraday’s law of electromagnetic induction. It utilizes time-varying magnetic fields to generate induced currents within tissues, thereby modulating the excitability and physicochemical properties of pelvic floor neuromuscular structures. Similar to wireless charging for mobile phones, magnetic stimulation can non-invasively penetrate clothing, skin, bone, and adipose tissue. This promotes pelvic nerve remodeling, enhances blood circulation, and exercises pelvic floor muscles, ultimately improving clinical symptoms associated with pelvic floor dysfunction disorders.

Next is “deeper.”The MiCi Pro delivers a maximum magnetic field strength of 7.2 T and a maximum output frequency of 100 Hz, with a magnetic stimulation depth reaching 8–12 cm subcutaneously. “This is significantly deeper than traditional electrical stimulation therapy, enabling effective targeting of the deep pelvic floor muscle groups. A single 20–30-minute session is equivalent to performing tens of thousands of Kegel exercises,” stated Gong Zhaoyong.

Furthermore, there is “broader.”Unlike traditional methods that only stimulate the inner vaginal wall, MiCi Pro features a treatment chair that enables patients to receive therapy immediately upon sitting, without cumbersome preparation, allowing magnetic fields to cover the entire pelvic floor muscle group. In particular, pelvic floor issues in women are often not isolated to a single site but involve dysfunction of the entire muscle group. To address this, MiCi Pro offers diverse treatment modes—including protocol-based therapy, composite mode, standard mode, and TBS mode—to meet personalized clinical treatment needs and provide more comprehensive solutions.

Finally, "Safer."“Traditional pelvic floor therapies (such as electrical stimulation) require the use of electrode heads, and the invasive treatment process may carry risks of infection and burns. In contrast, magnetic stimulation therapy does not require internal electrodes or probes, thereby avoiding the risks associated with invasive procedures. Furthermore, each session lasts only 25 minutes, with a typical course of treatment consisting of 6–8 sessions, which can visibly improve postpartum issues such as urinary incontinence,” explained Gong Zhaoyong.

Women’s intimate health, a field long relegated to the margins of public discourse, is emerging as a key sector within the broader health and wellness industry, driven by rising health awareness among modern women and increasingly diverse lifestyles.

On the demand side, women’s needs for intimate health have shifted from a singular focus on “disease treatment” to an integrated model of “prevention + management.” However, traditional intimate health management primarily relies on subjective descriptions and basic examinations, often making it difficult to achieve precise assessment and management.

Gong Zhaoyong pointed out: “Traditional test reports involve a large number of technical terms, making them difficult for ordinary users to understand. As a result, doctors need to spend considerable time interpreting the reports—typically 30–40 minutes per patient. We aim to leverage AI-driven innovations to help users gain a more intuitive understanding of their health status, while also alleviating the workload on physicians.”

Meixiu Medical AI Intimate Rejuvenation System

Meixiu Medical’s AI-powered intimate rejuvenation system, deployed locally via DeepSeek, can “interpret” intimate health reports with a single click within 10 seconds and further generate personalized health management recommendations based on each user’s specific condition. Moreover, thanks to its local deployment, the system offers superior advantages in data privacy and processing speed. Gong Zhaoyong emphasized, “We are not using AI to replace doctors, but rather leveraging AI tools to assist both physicians and users in interpreting reports, ultimately achieving more standardized testing, more personalized treatment plans, and more transparent decision-making.”

Interpretation of the AI Private Rejuvenation System Report

Specifically, the AI Intimate Rejuvenation System deeply integrates bioelectrical sensing, pressure sensing, and imaging technologies to construct a unique assessment ecosystem, with its core functions including“Dual Assessment + Dual Treatment”：

· Youthfulness Assessment:Precisely collect electromyographic (EMG) signals from the pelvic floor muscles across various phases, including pre-rest, fast- and slow-twitch muscle contractions, and progressive control, and quantify the data into the “One Degree, Four Forces” framework (excitability, explosive power, endurance, control, and relaxation).

· Tightness Assessment:Multidimensional measurement of key parameters such as the user's initial tension, incremental sustained contraction, and maximum tolerated volume, which are analyzed into the "One Degree, Three Properties" framework (tightness, fullness, elasticity, and compliance).

· Personalized Plan:Quantitative Assessment of the AI Private Rejuvenation System not only provides physicians with more comprehensive diagnostic evidence but also assists them in rapidly formulating more precise, personalized treatment plans based on the reports.

· Cyclic Electrical Stimulation:By simulating physiological cycles through pulsed current stimulation, cells are activated, thereby improving tissue blood supply and nutritional metabolism.

According to the “2025 White Paper on Women’s Intimate Health in China” released by iResearch, the global market for women’s intimate health is poised to enter a phase of rapid growth. The market size is projected to surpass RMB 1 trillion by 2027 and exceed RMB 2 trillion by 2030, with a compound annual growth rate (CAGR) of 17.5%, gradually emerging as the most resilient blue-ocean segment within the broader health and wellness industry.

This growth is not only driven by strong support from national policies such as the “Healthy China 2030” Plan and the Outline for the Development of Chinese Women (2021–2030), but also stems deeply from a comprehensive awakening of women’s health awareness.

Driven by the triple forces of policy, demand, and technology, Meixiu Medical has adopted a dual-track market strategy, focusing on both public hospitals and private institutions. In the domestic market, the company primarily promotes its offerings in the fields of rehabilitation and intimate rejuvenation management. In the international market, it distributes its products globally through channels such as its South Korean subsidiary, KOREA MAYSHU CO., LTD.

Leveraging its innovative technology, precise grasp of market demands, and relentless pursuit of superior user experience, the company has rapidly gained widespread recognition in the market. Currently, Meixiu Medical’s products are extensively sold in both domestic and international markets, with cumulative installations exceeding 5,000 units, including over 3,000 units in overseas markets. Its presence spans numerous countries, including the United States, France, Germany, Spain, the United Kingdom, Russia, and Brazil.

More importantly,Meixiu Medical's devices are now connected globally, enabling the company to monitor and maintain the operational status of each connected device in real time via its cloud platform.On one hand, the company can precisely drive product R&D and iteration based on the usage preferences and functional needs of users in different countries and regions, ensuring that device features align more closely with market demands. On the other hand, by leveraging device operational data and user feedback, the company can provide recommendations for service optimization to end-user institutions, helping them improve operational efficiency and customer satisfaction, thereby achieving better market performance.

Most failures of Meixiu medical products can be resolved through remote software upgrades (OTA),Currently, the global failure rate is within 0.2%.. This efficient remote maintenance capability not only significantly reduces after-sales costs but also greatly enhances user experience, ensuring that equipment remains in optimal operating condition at all times.

In terms of product planning, Meixiu Medical aims to develop products centered on the full lifecycle of women’s health. Starting with pelvic floor health, the company will gradually expand into areas such as ovarian function, body contouring, and facial anti-aging, continuously providing users with smarter and more convenient health management solutions.

Next, Meixiu Medical will prioritize the development of two products for the domestic market. The first isHome Pelvic Floor Magnetic Stimulation Therapy Device, this product aims to extend non-invasive magnetic stimulation technology to more households, providing users with convenient pelvic floor rehabilitation solutions; secondly,Ovarian Function Magnetic Stimulation Therapy Device, focusing on delaying the onset of menopause in women through scientific treatment methods, alleviating related symptoms, and improving women's health.

Looking ahead, Gong Zhaoyong stated, “Women’s intimate health is not only a personal issue but also a microcosm of social progress. Only by truly understanding women’s needs can brands, institutions, and individuals gain a competitive edge in this trillion-yuan blue ocean market. In the future, Meixiu Medical will continue to adhere to its dual-drive strategy of R&D innovation and internationalization, empowering the full lifecycle value of women’s health management.”